Prosecution Insights
Last updated: April 19, 2026

Cue Biopharma Inc.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18107265 MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF HUYNH, PHUONG N 1641 Non-Final OA Feb 08, 2023
18107244 MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF DIBRINO, MARIANNE 1641 Non-Final OA Feb 08, 2023
18005813 T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof QIAN, CELINE X 1637 Non-Final OA Jan 17, 2023
17927501 Antigen Presenting Polypeptide Complexes and Methods of Use Thereof VAN DRUFF, SYDNEY 1643 Non-Final OA Nov 23, 2022
17490516 MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF PATTERSON, SARAH COOPER 1675 Final Rejection Sep 30, 2021

Managing Cue Biopharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month